Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. (Q30353991)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 June 2017

Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant. (English)

1 reference

Europe PubMed Central

20 June 2017

0 references

4

object named as

Steven Reed

1 reference

Europe PubMed Central

20 June 2017

author name string

John J Treanor

1

1 reference

Europe PubMed Central

20 June 2017

Brandon Essink

2

1 reference

Europe PubMed Central

20 June 2017

Steven Hull

3

1 reference

Europe PubMed Central

20 June 2017

Ruvim Izikson

5

1 reference

Europe PubMed Central

20 June 2017

Peter Patriarca

6

1 reference

Europe PubMed Central

20 June 2017

Karen L Goldenthal

7

1 reference

Europe PubMed Central

20 June 2017

Robert Kohberger

8

1 reference

Europe PubMed Central

20 June 2017

Lisa M Dunkle

9

1 reference

Europe PubMed Central

20 June 2017

language of work or name

0 references

publication date

27 September 2013

1 reference

Europe PubMed Central

20 June 2017

1 reference

Europe PubMed Central

20 June 2017

31

1 reference

Europe PubMed Central

20 June 2017

48

1 reference

Europe PubMed Central

20 June 2017

5760-5765

1 reference

Europe PubMed Central

20 June 2017

Avian influenza A (H5N1) in 10 patients in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Airborne transmission of influenza A/H5N1 virus between ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

A fast track influenza virus vaccine produced in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.08.064

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.08.064

1 reference

Europe PubMed Central

20 June 2017

1 reference

Europe PubMed Central

20 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30353991&oldid=1976352303"